close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Biomea Fusion, Inc.

< Previous 1 2 3 Next >
News headline image
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Announces Proposed Public Offering of Common Stock
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
News headline image
Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today